How does the operation of PHARMAC's 'Community Exceptional ...

References
Abel, A., Mankew, G., Summers, L. H., & Zeckhouser, R. J. (1989). Assessing
Dynamic Efficiency Theory and Evidence. Review of Economic Studies
56(May), 1-20. doi: 0034-6527/89/00010001
Adams, I., & Dyson, R. W. (2004). Fifty Major Political Thinkers. London
Routledge
Adams, J., Khan, H.T.A., Raeside, R. & White, D. (2007) Research Methods for
Graduate Business and Social Science Students.Thousand Oaks,
California: Sage p170.
American Medical Association. (2007). Quick Reference Citation Format For
AMA. Manual of Style, 10th ed. Retrieved from
http://www4.samford.edu/schools/pharmacy/dic/amaquickref07.pdf
Accessed on 28/10/2011.
Aronson, J.K. (2006) Rare Diseases and Orphan Drugs. British Journal of
Clinical Pharmacology March; 61(3): 243-245 doi: 10.1111/j.1365-
2125.2006.02617.x
Ashton, T. (n.d.). Review of the 'Report to PHARMAC' by Paul Hansen and
Raanon Gillon. In C. b. PHARMAC (Ed.). Auckland: Published by School
of Population Health University of Auckland.
Ashton, T., Cumming, J., & Devlin, N. (1999). Prioritising health and disability
support services: principles processes and problems. A report to the
National Health Committee on the HFA’s proposed prioritisation process.
(P. 5,6). Wellington: Health Funding Authority.
Ashton, T., & St John, S. (2002). Running on the spot: Lessons from a decade
of health reform in NZ. Applied Health Economics and Health Policy,
1(2002), 47-56.
286